Incyte Corp (INCY) Stock Price, Quote & News

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 498 6700

Website: www.incyte.com

Address:

1801 Augustine Cut-Off, Wilmington, United States

Alpha_Ascendant Jul. 4 at 11:29 AM

$MIRM Up 188% since my first report, this biotech is performing, building a liver disease franchise with a clutch of approved drugs while promising pipeline candidates --Volixibat, MRM-3379, Brelovitug, Zilurgisertib-- quietly stalk endpoints. $INCY ti.e-up and Bluejay acquisition a plus: https://seekingalpha.com/article/4919805-mirm-this-liver-disease-juggernaut-just-broadened-its-portfolio

0 · Reply

BullsOnPrade Jul. 3 at 11:26 PM

$INCY it it to win-cy itit 👀

0 · Reply

peloswing Jul. 3 at 8:13 PM

Some large buys on September $INCY puts yesterday. $110 and $100 strikes 🔴

0 · Reply

MorganHoratio Jul. 2 at 9:57 PM

One of the strongest sectors outside of AI right now is Biotech. Oncology $PSNL Personalis $GH Guardant Health $NEO NeoGenomics $INCY Incyte Non-AI capital flows heavily into precision oncology and screening tech! Smart money triggers tactical limit entries atop long-term FIB volume floors, lock-floating diagnostic monopolies. Early-screening king GH leads the breakout on explosive Shield revenue and full-year guidance upgrades, while path-leader NEO secures NGS pathology profitability and PSNL firms up technical entries. Flanking them, biopharma vanguard INCY hardens its valuation ceiling following key European Opzelura backing. Clinical execution means nothing without scalable adoption and margins. Facing this oncology rotation, are you buying the FIB support floors or holding defensive cash? Drop your execution playbook below!

1 · Reply

Nomorelies Jun. 30 at 3:46 AM

$INCY Very

0 · Reply

JFais Jun. 29 at 5:07 PM

$SNDX - pullback to high teens was your gift, focus will be on upcoming IPF & frontline GvHD readouts $INCY

0 · Reply

JuggernautRaider Jun. 29 at 11:03 AM

$TNXP 1) Mark Cuban is a fraud. He only knows sales. His tech is 💩 2) you should sell Shitcoin. I think it peaked at $100K but who knows 3) I’m buying more TNXP before its third and final run of the past two years 🏃‍♂️ 4) Seth Lederman needs to retire as acting CEO. The board is feckless and pathetic. How do they still have their jobs? 5) i’ll be launching my Academy “platform” under my LLC to advise on any other stocks that my subscribers want 😊 This will be a great week. I am a free agent again - which means I can use my social media skills to make Seth and Tonix look bad at their jobs, while also informing you all more freely 🆓 The sales numbers just scratch the story of launch. I believe Tonmya can be a billion dollar franchise by itself. Just like Otezla at $AMGN , formerly of $BMY . This is no Jakafi from $INCY but with the right CEO… 🤔

0 · Reply

JuggernautRaider Jun. 27 at 5:22 AM

$ALLR $CCCC $KPTI $INCY hmm who will Incyte buy next? 💊 Vega Therapeutics will not sustain them for long … will it? 🤔

0 · Reply

SilverEagle Jun. 26 at 2:44 PM

$INCY up through 110

0 · Reply

Nomorelies Jun. 26 at 2:31 PM

$IBRX $INCY $BBIO $VKTX

1 · Reply

Incyte Shares Rise on EPS Growth, Lifted Guidance, Expansion

2026-06-26T11:35:08.000Z - 8 days ago

Incyte announces positive CHMP opinion of Opzelura Cream

Jun 26, 2026, 7:30 AM EDT - 8 days ago

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

2026-06-26T10:35:53.000Z - 8 days ago

Incyte price target raised to $113 from $103 at UBS

2026-06-22T17:50:37.000Z - 12 days ago

Incyte price target raised to $105 from $103 at Truist

2026-06-22T08:35:45.000Z - 12 days ago

Incyte upgraded to Market Perform from Underperform at BMO Capital

2026-06-19T11:10:35.000Z - 15 days ago

Incyte Japan announces approval of Minjuvi combination for DLBCL

$Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)$

Jun 19, 2026, 2:00 AM EDT - 15 days ago

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

2026-06-14T21:20:07.000Z - 19 days ago

Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study

MIRM

2026-06-14T21:15:33.000Z - 19 days ago

Incyte announces clinical data from two Phase 2 studies of INCA033989

2026-06-14T21:10:35.000Z - 19 days ago

Incyte announces results from Phase 3 frontMIND trial of tafasitamab

Jun 14, 2026, 4:35 PM EDT - 19 days ago

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

MIRM

Jun 13, 2026, 11:15 AM EDT - 21 days ago

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

Jun 13, 2026, 6:00 AM EDT - 21 days ago

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

Jun 9, 2026, 8:40 AM EDT - 25 days ago

Incyte Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T18:55:10.000Z - 25 days ago

Incyte price target raised to $107 from $90 at Oppenheimer

2026-06-08T18:00:44.000Z - 26 days ago

Jefferies sees positive readthroughs to Hemab Therapeutics from Incyte deal

COAG

Jun 8, 2026, 8:00 AM EDT - 26 days ago

Incyte Transcript: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 26 days ago

Incyte Press release: M&A announcement

Jun 8, 2026, 8:00 AM EDT - 26 days ago

Incyte Slides: M&A announcement

Jun 8, 2026, 7:34 AM EDT - 26 days ago

Incyte to Buy Vega Therapeutics For Up to $2 Billion

Jun 8, 2026, 7:07 AM EDT - 26 days ago

Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary

2026-06-08T11:06:31.000Z - 26 days ago

Incyte to acquire Vega Therapeutics for $1.25B

Jun 8, 2026, 7:00 AM EDT - 26 days ago

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

Jun 7, 2026, 6:11 AM EDT - 27 days ago

Incyte nears up to $2 billion deal for blood disorder biotech Star, FT reports

2026-06-04T12:21:26.000Z - 4 weeks ago

Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026

MIRM

2026-05-31T13:30:07.000Z - 4 weeks ago

Incyte announces results from Phase 3 frontMIND trial on tafasitamab

May 30, 2026, 8:02 AM EDT - 5 weeks ago

Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate

May 30, 2026, 8:00 AM EDT - 5 weeks ago

Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Incyte Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 5 weeks ago

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

2026-05-21T21:15:27.000Z - 6 weeks ago

Bernstein starts Incyte at MarketPerform, sees no clear path for revenue rebound

2026-05-21T20:27:18.000Z - 6 weeks ago

Incyte initiated with a Market Perform at Bernstein

May 20, 2026, 12:10 PM EDT - 6 weeks ago

Inside Incyte's $120 Million AI For Drug Development Deal

2026-05-20T12:19:27.000Z - 6 weeks ago

Incyte, Genesis Molecular AI announce expansion of collaboration

May 20, 2026, 8:00 AM EDT - 6 weeks ago

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

May 19, 2026, 10:30 AM EDT - 6 weeks ago

Incyte Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-19T12:13:08.000Z - 6 weeks ago

Incyte, Edison Scientific announce strategic collaboration to employ Kosmos

May 19, 2026, 8:00 AM EDT - 6 weeks ago

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

May 13, 2026, 4:40 PM EDT - 7 weeks ago

Incyte Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 9:30 AM EDT - 7 weeks ago

Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress

2026-05-07T19:58:38.000Z - 2 months ago

Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial

May 7, 2026, 8:50 AM EDT - 2 months ago

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

May 6, 2026, 4:30 PM EDT - 2 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026, 5:28 PM EDT - 2 months ago

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Apr 29, 2026, 8:00 AM EDT - 2 months ago